黄片一区二区三区在线观看-亚洲av综合久久国产激情按摩店-欧美日韩国产长车超污-欧美日韩偷拍精品视频

首頁 > 產(chǎn)品目錄 > 信號(hào)通路 > Angiogenesis > VEGFR > 法瑞西單抗

法瑞西單抗

Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)

產(chǎn)品編號(hào):CLA1508 CAS No.:1607793-29-2 MDLNo: 分子式: 分子量:
規(guī)格 庫存 目錄價(jià) 會(huì)員專享價(jià) 數(shù)量

暫無牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。

化學(xué)品安全說明書(MSDS)

下載MSDS
  • 基本信息
  • 相關(guān)文檔
  • 產(chǎn)品詳情
  • 相關(guān)文獻(xiàn)
基本信息
英文名稱 Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)
中文名稱法瑞西單抗
CAS號(hào)1607793-29-2
儲(chǔ)存條件store at -20°C
產(chǎn)品詳情

Faricimab is a pioneering humanized bispecific antibody that targets both VEGF-A and Ang-2, offering a dual inhibition approach for retinal diseases like DME and nAMD. By inhibiting VEGF-A, it reduces endothelial cell proliferation and vascular permeability, while blocking Ang-2 is believed to enhance vascular stability and counteract VEGF-A effects. Faricimab has demonstrated a significant reduction in annual injections compared to other anti-VEGF treatments, with a comparable efficacy and safety profile, positioning it as a valuable treatment option for patients with retinal diseases.


相關(guān)產(chǎn)品
抱歉,暫時(shí)沒有相關(guān)產(chǎn)品
在線客服
小德
021-58180488
小立
021-58180488
在線服務(wù)時(shí)間: 工作日 9:00-18:00